Stereotaxis, a global leader in surgical robotics for minimally invasive endovascular procedures, has signed a definitive agreement to acquire Robocath, a French developer of robotic technologies for interventional cardiology and neurointerventions.

 

The deal marks a significant push by Stereotaxis to strengthen its position across the full spectrum of endovascular procedures by combining complementary robotic technologies into a more unified platform spanning electrophysiology, interventional cardiology, and neurointerventions.

 

“Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures,” said David Fischel, Stereotaxis Chairman and CEO. 

 

“By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine. This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.”

 

Robocath, based in Rouen, has developed mechanical robotic systems for interventional cardiology and neurovascular procedures. Its flagship R-One+ system is currently the only commercially available robotic solution for percutaneous coronary interventions in Europe, with 15 systems installed globally. 

 

The company is also developing a next-generation platform capable of controlling up to five interventional devices simultaneously, with early first-in-human procedures recently completed in France.

 

“For over fifteen years, we have been committed to pioneering the most sophisticated plug-and-play bionic robotic technology for endovascular procedures,” said Philippe Bencteux, Robocath Founder and CEO. 

 

“Joining Stereotaxis provides the scale, complementary technologies, and strategic alignment needed to accelerate our development and expand our impact. We believe this combination will unlock significant opportunities in rapidly growing markets, which are becoming increasingly receptive to robotics.”

 

Stereotaxis said the combined technologies—its magnetic navigation system and Robocath’s mechanical robotic platform—will create a fully integrated robotic solution for endovascular surgery. While Stereotaxis enables precise catheter navigation using magnetic fields, Robocath’s system adds bedside multi-device control, with both platforms expected to work in tandem.

 

“There is defined value to each technology on a standalone basis. Together, these technologies offer a powerful and synergistic approach to improving procedural precision, efficiency, and outcomes,” the company said.

 

Stereotaxis plans to accelerate development of Robocath’s next-generation system and pursue regulatory submissions in the United States and Europe within two years. It also intends to integrate its own proprietary systems—including GenesisX, Synchrony, and SynX—to add operating room integration, automation, and remote procedure capabilities.

 

The combined platform is expected to expand into electrophysiology over time.

 

Financially, Stereotaxis expects Robocath to contribute about $2 million in annual revenue in the first year post-acquisition, with the deal projected to break even by year three through synergies.

 

The transaction includes an upfront payment of $20 million, plus up to $25 million in milestone-based payments tied to regulatory and commercial achievements, including FDA clearance of Robocath’s next-generation system. Payment may be made in cash or stock at Stereotaxis’ discretion.

 

“The acquisition is subject to customary closing conditions and is expected to close in mid-2026. Upon closing, Robocath will operate as a wholly owned subsidiary of Stereotaxis,” the companies said.

 

“We are delighted to welcome the accomplished Robocath team to Stereotaxis,” Fischel added. “This acquisition is a reflection of our commitment to technological leadership across endovascular robotics, with continued investment in significant innovations that improve access, efficiency, and outcomes of minimally-invasive cardiovascular and neurovascular therapies.”